



Vivimed

Date:30/05/2015

To

BSE Limited
Listing Department
P.J.Towers,Dalal Street,
Mumbai – 400001

National Stock Exchange of India Ltd
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra(E),Mumbai – 400051

NSE- Symbol: VIVIMEDLAB

BSE - Scripe Code : 532660

Dear Sir/Madam

Sub: Outcome of the Meeting of the Board of Directors of the Company – reg

The Board of Directors of the Company at its meeting held on May 30, 2015, inter alia, have approved the following :

1. Pursuant to clause 41 of Listing Agreement entered into with the stock exchange, considered and approved the submission of the audited Financial Results (Standalone & Consolidated) for the Quarter ended March 31,2015 and Audited financial results (Standalone& Consolidated) for the Year ended March 31,2015 attached herewith;
2. The Board took note of Auditor's Report on the Audited Financial Statements of the Company for the financial year ended March 31, 2015
3. No Dividend is recommended for the Financial Year 2014-15

An earnings related presentation including business highlights will be uploaded on the company's website www.vivimedlabs.com
You are requested to take note of the above.

Yours faithfully

For VIVIMED LABS LTD


SANTOSH VARALWAR
MANAGING DIRECTOR & CEO



Vivimed Labs Ltd (Corporate Office)

CIN : L02411KA1988PLC009465

Veernag Towers, Habsiguda, Hyderabad, Telangana - 500 007, India

T +91 (0) 40-2717 6005/6 F +91 (0) 40-2715 0599

contact@vivimedlabs.com www.vivimedlabs.com

VIVIMED LABS LIMITED
CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED MARCH 31'ST 2015

Rs in Lacs

Sl. No.	Particulars	Quarter Ended			For the year Ended	
		31.03.2015	31.12.2014	31.03.2014	31.03.2015	31.03.2014
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Income From Operations					
	(a) Net Sales / Income from Operations (Net of Excise Duty)	35,621.52	34,370.89	36,817.32	1,38,009.91	1,35,083.30
	(b) Other Operating Income	49.75	98.62	390.42	586.57	821.51
	Total Income From Operations (Net)	35,671.27	34,469.51	37,207.74	1,38,596.49	1,35,904.81
	a. Cost of Raw Materials Consumed	17,159.03	17,292.61	19,033.52	69,931.61	66,370.82
	b. Purchase of Stock in Trade					
	c. Changes in Inventories of finished Inventories of Finished Goods, Work-in-Progress and Stock in Trade	(425.78)	(1,516.56)	(2,985.16)	(5,309.20)	(738.38)
	d. Employee Benefit Expenses	4,721.12	4,780.18	4,123.32	18,442.79	17,206.48
	e. Depreciation and Amortisation Expenses	1,470.70	1,843.10	1,714.96	6,617.76	6,611.62
	f. Other Expenditure	8,954.15	7,886.57	11,191.59	33,256.12	31,739.01
2	Total Expenses	31,879.21	30,285.90	33,078.23	1,22,939.08	1,21,189.55
3	Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)	3,792.06	4,183.61	4,129.51	15,657.41	14,715.26
4	Other Income	-	-	-	-	-
5	Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)	3,792.06	4,183.61	4,129.51	15,657.41	14,715.26
6	Finance Costs	2,157.28	1,937.23	1,763.49	7,903.68	6,029.10
7	Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)	1,634.78	2,246.38	2,366.02	7,753.73	8,686.16
8	Exceptional items	-	-	-	-	-
9	Profit / Loss from ordinary activities before Tax (7 - 8)	1,634.78	2,246.38	2,366.02	7,753.73	8,686.16
10	Tax Expenses	(160.04)	190.28	1,261.85	548.69	2,046.76
11	Net Profit / Loss from ordinary activities after Tax (9 - 10)	1,794.82	2,056.09	1,104.17	7,205.04	6,639.41
12	Extraordinary Items (net of tax expenses Rs.....Lacs)	-	-	-	-	-
13	Net Profit / Loss for period (11 - 12)	1,794.82	2,056.09	1,104.17	7,205.04	6,639.41
14	Share of Profit / (Loss) of associates	-	-	-	-	-
15	Minority interest	-	-	-	-	-
16	Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)	1,794.82	2,056.09	1,104.17	7,205.04	6,639.41
17	Paid up Equity Share Capital (Face value of the Share shall be indicated)	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38
18	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year	-	-	-	-	-
19	Earnings per Share (before Extraordinary Items) (of Rs...../- each) (not annualised)	-	-	-	-	-
	(a) Basic	11.08	12.69	6.81	44.47	40.97
	(b) Diluted	11.08	12.69	6.81	44.47	40.97

1. The above Consolidated Audited Financial Results for the quarter & Year ended MARCH 31st, 2015 have been reviewed by Audit committee and taken on record by Board of Directors at their meeting held on 30th May 2015

2. Consolidated Financial Statements have been prepared in accordance with Accounting Standard-21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz., (i) Creative Healthcare Private Limited, (ii) Vivimed Labs USA, Inc., (iii) Kior Selien Private Limited, (iv) Octantis Nobel Labs Private Limited, (v) Vivimed Labs (Alathur) pvt Limited (vi) Finose Pharma pvt Limited and its step down subsidiaries viz. (vii) Vivimed Holdings Limited and its stepdown subsidiary Vivimed Labs Europe Limited (viii) Vivimed Labs Mauritius Limited and its stepdown subsidiaries (i) Vivimed Labs UK Limited, (ii) Vivimed Labs Spain, S.L. (iii) Union Quimico Farmaceutica S.A.U., Spain. (iv) Holiday International Limited, UK & (v) Uauifa Mexico S.A. de C.V.

3. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.

4. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments: "Specialty Chemicals" and "Pharma" are reported.

5. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

6. The company has calculated depreciation as per the provisions of companies act of 2013.

Place : Hyderabad
Date : 30.05.2015

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR & CEO



VIVIMED LABS LIMITED

SEGMENT-WISE CONSOLIDATED FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE LISTING AGREEMENT

Rs in Lacs

Particulars	3 Months Ended		For the year Ended		
	31.03.2015 (Audited)	31.12.2014 (Unaudited)	31.03.2014 (Audited)	31.03.2015 (Audited)	31-03-2014 (Audited)
1. Segment Revenue (net sales/income from each segment should be disclosed under this head)					
a.Speciality Chemicals Business	14,966.54	10,925.98	11,835.46	44,620.88	41,431.92
b.Pharma Business	20,654.98	23,444.91	24,981.86	93,389.04	93,651.38
Total	35,621.52	34,370.89	36,817.32	1,38,009.91	1,35,083.30
Less, Inter Segment Revenue				-	
Net sales / Income from Operations	35,621.52	34,370.89	36,817.32	1,38,009.91	1,35,083.30
2.Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment					
a.Speciality Chemicals Business	2,186.23	2,679.88	2,367.02	9,004.64	8,261.30
b.Pharma Business	1,605.83	1,503.73	1,762.50	6,652.77	6,453.96
Total	3,792.06	4,183.61	4,129.51	15,657.41	14,715.26
Less: 1.Interest	2,157.28	1,937.23	1,763.49	7,903.68	6,029.10
2.Other Un-allocable Expenditure			-		
3.Un-allocable Income			-		
Total Profit Before Tax	1,634.78	2,246.38	2,366.02	7,753.73	8,686.16
3. Capital Employed					
a.Speciality Chemicals Business	80,489.58	80,202.21	80,029.16	80,489.58	80,029.16
b.Pharma Business	68,208.23	62,269.98	67,372.76	68,208.23	67,372.76
Total	1,48,697.80	1,42,472.19	1,47,401.92	1,48,697.80	1,47,401.92

Place : Hyderabad
Date : 30.05.2015

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR & CEO



VIVIMED LABS LIMITED
STANDALONE FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED MARCH 31'ST 2015

Rs in Lacs

Sl. No.	Particulars	Quarter Ended			For the year Ended	
		31.03.2015	31.12.2014	31.03.2014	31.03.2015	31.03.2014
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Income From Operations					
	(a) Net Sales / Income from Operations (Net of Excise Duty)	12,641.27	10,527.52	12,781.01	43,014.81	43,199.35
	(b) Other Operating Income	46.72	58.24	72.03	143.40	154.99
	Total Income From Operations (Net)	12,687.99	10,585.76	12,853.03	43,158.21	43,354.34
	a. Cost of Raw Materials Consumed	5,848.41	6,712.00	6,830.70	25,110.30	23,605.69
	b. Purchase of Stock in Trade	-	-	-	-	-
	c. Changes in Inventories of finished Inventories of Finished Goods, Work-in-Progress and Stock in Trade	198.75	(2,048.74)	(516.74)	(5,319.45)	(140.95)
	d. Employee Benefit Expenses	784.72	624.01	215.43	2,788.34	1,983.25
	e. Depreciation and Amortisation Expenses	492.55	663.71	454.71	2,056.04	1,806.35
	f. Other Expenditure	3,088.61	2,404.14	3,264.68	9,863.94	7,784.86
2	Total Expenses	10,413.04	8,355.12	10,248.79	34,499.17	35,039.22
3	Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)	2,274.95	2,230.64	2,604.24	8,659.04	8,315.12
4	Other Income					
5	Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)	2,274.95	2,230.64	2,604.24	8,659.04	8,315.12
6	Finance Costs	1,599.98	1,714.03	1,492.65	6,233.53	4,434.39
7	Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)	674.97	516.61	1,111.59	2,425.51	3,880.73
8	Exceptional items					
9	Profit / Loss from ordinary activities before Tax (7 - 8)	674.97	516.61	1,111.59	2,425.51	3,880.73
10	Tax Expenses	115.20	103.33	663.98	531.99	1,217.81
11	Net Profit / Loss from ordinary activities after Tax (9 - 10)	559.77	413.28	447.61	1,893.52	2,662.92
12	Extraordinary Items (net of tax expenses Rs.....Lacs)					
13	Net Profit / Loss for period (11 - 12)	559.77	413.28	447.61	1,893.52	2,662.92
14	Share of Profit / (Loss) of associates					
15	Minority Interest					
16	Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)	559.77	413.28	447.61	1,893.52	2,662.92
17	Paid up Equity Share Capital (Face value of the Share shall be indicated)	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38
18	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year					
19	Earnings per Share (before Extraordinary Items) (of Rs...../- each) (not annualised)					
	(a) Basic	3.45	2.55	2.76	11.69	16.43
	(b) Diluted	3.45	2.55	2.76	11.69	16.43

1. The above Standalone Audited Financial Results for the quarter & year ended MARCH'31'ST 2015 have been reviewed by Audit committee and taken on record by Board of Directors at their meeting held on 30'th MAY '2015

2. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.

3. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.

4. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

5. The company has calculated depreciation as per the provisions of companies act of 2013.

6. This quarter is the balancing figure of the YTD and the reported for last quarter.

Place : Hyderabad
Date : 30.05.2015

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR & CEO




VIVIMED LABS LIMITED
SEGMENT-WISE STANDALONE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE LISTING AGREEMENT

Rs in Lacs

Particulars	3 Months Ended			FY 15	FY 14
	31.03.2015	31.12.2014	31.03.2014	31.03.2015	31-03-2014
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1. Segment Revenue (net sales/income from each segment should be disclosed under this head)					
a.Speciality Chemicals Business	10,866.81	8,060.31	10,440.43	34,941.15	35,112.23
b.Pharma Business	1,774.46	2,467.21	2,340.58	8,073.66	8,087.12
Total	12,641.27	10,527.52	12,781.01	43,014.81	43,199.35
Less, Inter Segment Revenue		-			
Net sales / Income from Operations	12,641.27	10,527.52	12,781.01	43,014.81	43,199.35
2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment					
a.Speciality Chemicals Business	2,000.46	1,873.78	1,948.70	7,271.32	6,772.07
b.Pharma Business	274.49	356.86	655.55	1,387.72	1,543.05
Total	2,274.95	2,230.64	2,604.24	8,659.04	8,315.12
Less: 1.Interest	1,599.98	1,714.03	1,492.65	6,233.53	4,434.39
2.Other Un-allocable Expenditure		-			
3.Un-allocable Income		-			
Total Profit Before Tax	674.97	516.61	1,111.59	2,425.51	3,880.73
3. Capital Employed					
a.Speciality Chemicals Business	81,345.51	77,390.65	80,431.84	81,345.51	80,431.84
b.Pharma Business	31,889.23	29,567.82	29,180.79	31,889.23	29,180.79
Total	1,13,234.74	1,06,958.47	1,09,612.63	1,13,234.74	1,09,612.63

Place : Hyderabad
Date : 30.05.2015

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR & CEO



VIVIMED LABS LIMITED

AUDITED STANDALONE & CONSOLIDATED BALANCE SHEET AS AT MARCH'31st,2015

Rs in Lacs


S.No	Particulars	STANDALONE		CONSOLIDATED	
		As at	As at	As at	As at
		31.03.2015 (Audited)	31.03.2014 (Audited)	31.03.2015 (Audited)	31.03.2014 (Audited)
(A)	EQUITY AND LIABILITIES				
1	Shareholders funds				
	(a) Share Capital				
	i) Equity Share Capital	1,620.38	1,620.38	1,620.38	1,620.38
	ii) Preference Share capital			6,394.56	6,394.56
	(b) Reserves and Surplus	35,774.58	35,622.03	47,908.55	47,783.95
	(c) Money Received against Share Warrants	-	237.20		237.20
	Sub Total Shareholders Funds	37,394.96	37,479.61	55,923.49	56,036.10
2	Non-current liabilities				
	a) Long-term borrowings	30,780.73	29,127.69	49,524.20	41,972.65
	(b) Deferred tax liabilities (net)	3,154.78	3,108.09	937.13	2,545.99
	(c) Other long-term liabilities	12,989.65	9,781.42	4,749.09	8,223.17
	(d) Long-term provisions	301.05	235.27	316.96	515.71
	Sub-total - Non-current liabilities	47,226.20	42,252.47	55,527.38	53,257.51
3	Current liabilities				
	(a) Short-term borrowings	28,613.58	27,633.86	37,246.93	37,543.33
	(b) Trade payables	4,359.31	3,925.56	18,871.38	19,049.39
	(c) Other current liabilities	10,166.27	7,508.23	17,637.68	13,878.28
	(d) Short-term provisions	2,515.40	1,542.44	4,638.95	3,971.43
	Sub-total - Current liabilities	45,654.55	40,610.09	78,394.93	74,442.43
	TOTAL - EQUITY AND LIABILITIES	1,30,275.71	1,20,342.17	1,89,845.81	1,83,736.04
(B)	ASSETS				
1	Non-current assets				
	(a) Fixed assets				
	(i) Tangible Assets	36,466.11	38,412.16	69,629.81	70,777.11
	(ii) Intangible Assets	1,189.17	1,321.30	11,717.24	10,014.87
	(iii) Capital work in progress	6,327.21	1,551.39	9,028.16	3,811.81
	(b) Non Current Investment	23,004.55	22,754.55	270.00	24.35
	(c) Long Term Loans and advances				
	(d) Other Non Current Assets			4.37	2,018.27
	Sub-total - Non-current assets	66,987.04	64,039.40	90,649.59	86,646.42
2	Current Assets				
	(a) Inventories	22,249.87	17,013.18	43,143.27	42,666.00
	(b) Trade receivables	22,807.52	18,379.19	32,957.80	34,782.58
	(c) Cash and cash equivalents	1,399.45	1,325.88	2,667.07	3,457.25
	(d) Short-term loans and advances	16,238.69	18,991.38	18,521.29	13,949.47
	(e) Other current assets	593.14	593.14	1,906.78	2,234.32
	Sub-total - Current assets	63,288.67	56,302.77	99,196.22	97,089.62
	TOTAL - ASSETS	1,30,275.71	1,20,342.17	1,89,845.81	1,83,736.04



Part II						
Select Information for the Quarter and Year Ended 31/03/2015						
SL.No	Particulars	Quarter ended 31/03/2015	Quarter ended 31/12/2014	Quarter ended 31/03/2014	Year ended 31/03/2015	Year ended 31/03/2014
A	PARTICULARS OF SHAREHOLDING					
	Public Shareholding					
	Number of Shares	10059058	10031058	10026058	10059058	10026058
	Percentage of Shareholding	62.08%	61.91%	61.87%	62.08%	61.87%
	Promoter and Promoter Group Shareholding					
	(a) Pledged/ Encumbered					
	Number of Shares	4823000	4079645	2482455	4823000	2482455
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	78.49%	66.09%	40.18%	78.49%	40.18%
	Percentage of shares (as a % of the total share capital of the company)	29.76%	25.18%	15.32%	29.76%	15.32%
	(b) Non-encumbered					
	Number of Shares	1321725	2093080	3695270	1321725	3695270
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	21.51%	33.91%	59.82%	21.51%	59.82%
	Percentage of shares (as a % of the total share capital of the company)	8.16%	12.91%	22.81%	8.16%	22.81%

Investor's Complaints

Sl.no	Particulars	3 months ended 31/03/2015
B	Pending at the beginning of the quarter	Nil
	Received during the quarter	Nil
	Disposed of during the quarter	Nil
	Remaining unresolved at the end of the quarter	Nil





P. MURALI & CO.,

CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470

Fax : (91-40) 2339 2474

E-mail : pmurali.co@gmail.com
info@pmurali.com

Website : www.pmurali.com

Auditor's Report On Quarterly Consolidated Financial Results and Consolidated Year to Date Results of VIVIMED LABS LIMITED Pursuant to the Clause 41 of the Listing Agreement

To
Board of Directors of
VIVIMED LABS LIMITED

We have audited the quarterly consolidated financial results of M/s VIVIMED LABS LIMITED (the company) and its subsidiaries (collectively referred to as "VIVIMED GROUP") for the quarter ended 31st March, 2015 and the consolidated year to date results for the period from 01st April, 2014 to 31st March, 2015 attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These consolidated quarterly financial results as well as the consolidated year to date financial results have been prepared from consolidated interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these consolidated financial results based on our audit of such consolidated interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, specified under section 133 of the act, read with rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India; our audit of the annual financial statements as at and for the year ended March 31, 2015; and the relevant requirements of clause 41 of the listing agreement.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

We did not audit the financial statements and financial information of the Subsidiary Companies which are included in the consolidated quarterly financial results and consolidated year to date results, whose consolidated interim financial statements reflect total assets of Rs. 2,05,599. 56 Lakhs as at 31st March, 2015 as well as the total revenue of Rs. 1,02,052.12 lakhs as at 31st March, 2015. These include Audited Interim financial statements and other financial information in respect of some of the subsidiaries whose audit reports are yet to be received and whose financial information and statements have been furnished to us by the management, and our opinion on the quarterly financial results and the year to date results, to the extent they have been derived from such interim financial statements is based solely on such unaudited financial statements and other financial information.





P. MURALI & CO.,

CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

In our opinion and to the best of our information and according to the explanations given to us these consolidated quarterly financial results as well as the consolidated year to date financial results:

1. Include the quarterly financial results and year to date of the following entities;
 - (A) Finoso pharma Pvt Ltd
 - (B) Vivimed Labs (Alathur) Pvt Ltd
 - (C) Creative Health Care Pvt Ltd
 - (D) Octanttisb Nobel labs Pvt Ltd
 - (E) KlarSehen Pvt Ltd
 - (F) Vivimed Holdings Ltd, Honkong
 - (G) Vivimed Labs Europe Ltd UK
 - (H) Vivimed Labs Mauritius Ltd
 - (I) Vivimed Labs UK Ltd
 - (J) Vivimed Labs Spain S.L
 - (K) Union Quimico Farmaceutica (Uquifa Spain)
 - (L) Holiday International Limited UK
 - (M)Uquifa Mexico S.A de.C.V
 - (N) Vivimed Labs USA Inc
2. have been presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
3. give a true and fair view of the net profit and other financial information for the quarter ended 31st March 2015, as well as the year to date results for the period from 1st April 2014 to 31st March 2015.

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the consolidated number of shares as well as percentage of shareholdings in respect of aggregate amount of consolidated public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

Place: Hyderabad
Date: 30th May 2015



For P. Murali & Co.,
Chartered Accountants
FRN: 007257S


P.Murali Mohana Rao
Partner
M No. 023412



P. MURALI & CO.,

CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

Auditor's Report on Quarterly Financial Results and Year to Date Financial Results of Vivimed Labs Limited pursuant to the Clause 41 of the Listing Agreement

To,
The Board of Directors of **Vivimed Labs Limited**

1. We have audited the quarterly financial results of **Vivimed Labs Limited** for the quarter ended March 31, 2015 and to the year to date financial results for the year ended March 31, 2015, attached herewith, being submitted by the Company pursuant to the requirement of Clause 41 of the Listing Agreement, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. The quarterly financial results are the derived figures between the audited figures in respect of the year ended March 31, 2015 and the published year-to-date figures up to December 31, 2014, being the date of the end of the third quarter of the current financial year, which were subject to limited review. The financial results for the quarter ended March 31, 2015 have been prepared on the basis of the financial results for the nine-month period ended December 31, 2014, the audited annual financial statements as at and for the year ended March 31, 2015, and the relevant requirements of Clause 41 of the Listing Agreement and are the responsibility of the Company's management and have been approved by the Board of Directors of the Company. Our responsibility is to express an opinion on these Financial results based on our review of the financial results for the nine-month period ended December 31, 2014 which was prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, specified under section 133 of the act, read with rule 7 of the companies(Accounts) Rules 2014 and other accounting principles generally accepted in India; our audit of the annual financial statements as at and for the year ended March 31, 2015; and the relevant requirements of clause 41 of the listing agreement.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
3. In our opinion and to the best of our information and according to the explanations given to us, these quarterly financial results as well as the year to date financial results:
 - (i) are presented in accordance with the requirements of Clause 41 of the Listing agreement in this regard; and
 - (ii) give a true and fair view of the net profit and other financial information for the quarter ended March 31, 2015 as well as the year to date results for the period from April 1, 2014 to March 31, 2015.

L





P. MURALI & CO.,

CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

4. Further, read with paragraph 1 above, we report that the figures for the quarter ended March 31, 2015 represent the derived figures between the audited figures in respect of the financial year ended March 31, 2015 and the published year-to-date figures up to December 31, 2014, being the date of the end of the third quarter of the current financial year, which were subjected to a limited review as stated in paragraph 1 above, as required under Clause 41 (I)(d) of the Listing Agreement.
5. Further, read with paragraph 1 above, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For P. Murali & Co.,
Chartered Accountants
Firm's Registration number: 007257S

P. Murali Mohana Rao

P. Murali Mohana Rao
Partner
M.No. 023412



Place: Hyderabad
Date: 30/05/2015